Cysteamine hydrochloride - Generic Drug Details

What are the generic drug sources for cysteamine hydrochloride and what is the scope of freedom to operate?

Cysteamine hydrochloride is the generic ingredient in two branded drugs marketed by Recordati Rare and Leadiant Biosci Inc, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for cysteamine hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	32
What excipients (inactive ingredients) are in cysteamine hydrochloride?	cysteamine hydrochloride excipients list
DailyMed Link:	cysteamine hydrochloride at DailyMed

Recent Clinical Trials for cysteamine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Thiogenesis Therapeutics, Inc.	PHASE2
Nacuity Pharmaceuticals, Inc.	Phase 1/Phase 2
Cosmetique Active International	NA

See all cysteamine hydrochloride clinical trials

Pharmacology for cysteamine hydrochloride

Drug Class	Cystine Depleting Agent
Mechanism of Action	Cystine Disulfide Reduction

US Patents and Regulatory Information for cysteamine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	CYSTADROPS	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	211302-001	Aug 19, 2020		RX	Yes	Yes
Leadiant Biosci Inc	CYSTARAN	cysteamine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	200740-001	Oct 2, 2012		RX	Yes	Yes

Market Dynamics and Financial Trajectory for Cysteamine Hydrochloride

Last updated: February 13, 2026

Cysteamine hydrochloride (cysteamine HCl) is a drug approved primarily for the treatment of nephropathic cystinosis, a rare genetic disorder characterized by excessive cystine accumulation in cells. Its commercial landscape is shaped by regulatory status, patent activity, clinical applications, and competitive pressures.

---

Regulatory and Patent Landscape

• FDA Approval: Cysteamine HCl has received FDA approval since 1994 for cystinosis management. Multiple formulations exist, including caplets and topical solutions, with opportunities for new formulations or delivery methods.
• Patent Status: Several patents related to formulations and methods expired or are nearing expiration. The original patents expired in the late 2000s. Patents covering specific formulations and uses may still be active in certain jurisdictions, affecting generic entry timelines.
• Regulatory Strategy: Development of modified-release formulations or combination therapies can extend market exclusivity. No recent major regulatory hurdles have been reported.

---

Market Size and Growth Drivers

• Addressable Population: The rare nature of cystinosis limits the total addressable market. An estimated 1 in 100,000 to 200,000 live births manifests cystinosis globally. Prevalence estimates suggest approximately 2,000-3,000 diagnosed cases worldwide.
• Market Value: The cysteamine market was valued at around $124 million in 2021, with projections reaching approximately $150 million by 2026, growing at a compounded annual growth rate (CAGR) of 3.5% (Mordor Intelligence).
• Key Drivers:
  • Improved diagnostics increasing diagnosed cases.
  • Adoption of extended-release formulations to enhance adherence.
  • Potential expansion into other indications like non-nephropathic cystinosis or related cystine storage disorders.
  • Growing awareness and treatment adherence initiatives.

---

Competitive Dynamics

• Market Participants:
  • MyoClin, Inc.: Produces the existing branded cysteamine products.
  • Generic Manufacturers: Multiple companies are developing or marketing generic versions, which influence pricing and market share.
  • Innovators: Companies exploring alternative delivery systems (e.g., transdermal patches, injectables) to improve patient compliance.
• Pricing Trends: List prices hover around $10,000–$20,000 annually per patient for branded formulations, with significant discounts available through insurers and patient assistance programs.
• Market Share: Branded drugs dominate initially post-patent expiration but face rapid erosion as generics enter.

---

Revenue and Financial Outlook

• Historical Revenue: Estimated sales of cysteamine HCl products between $120 million and $130 million annually over the past three years.
• Future Revenue Trends: Slight declines expected from generic erosion unless new formulations or indications are commercialized.
• Investment and R&D Spend: Companies invest in formulation improvements and exploration of new therapeutic uses; however, high R&D costs yield uncertain returns due to small patient populations.
• Pricing Pressure: As patents expire, generic competition drives down prices, reducing profit margins for original developers.

---

Challenges and Opportunities

• Challenges:
  • Limited patient population constrains revenue potential.
  • Patent expirations accelerate generic entry.
  • Competition from new therapies targeting cystinosis or alternative diseases.
• Opportunities:
  • Developing sustained-release or alternative delivery options.
  • Expanding into off-label or secondary indications.
  • Collaborations with research institutes for rare disease research.

---

Future Outlook

The market for cysteamine hydrochloride remains modest due to the rarity of cystinosis but retains stability owing to its essential role in treatment. The main growth opportunities hinge on formulation innovation and expansion into additional cystine-related disorders. Revenue stability is threatened by patent expirations and generic competition, which are likely to lead to a declining trend unless new value-added innovations are introduced.

---

Key Takeaways

• Cysteamine hydrochloride is a niche, yet critical therapy for cystinosis with a market valued at approximately $124 million in 2021.
• The market size is limited by the rare disease prevalence but benefits from steady demand due to the absence of alternatives.
• Patent expirations and generic competition are primary factors influencing revenue decline.
• Formulation improvements and new indications offer growth pathways, though R&D investments are risky given the small patient base.
• Pricing pressures and insurance negotiations significantly impact profitability for manufacturers.

---

FAQs

Q1: What is the primary clinical use of cysteamine hydrochloride?

A1: It treats cystinosis, preventing cystine accumulation in lysosomes.

Q2: When are most patents related to cysteamine HCl expected to expire?

A2: Patents expired or are expiring in the late 2000s to early 2010s; remaining patents cover specific formulations and uses, potentially extending exclusivity into the early 2030s.

Q3: What are the main drivers of growth in the cysteamine market?

A3: Increased diagnosis, new formulations improving patient compliance, and expanded indications.

Q4: How does patent expiration affect the market?

A4: It typically leads to a surge in generic product entry, causing price reductions and revenue declines for originators.

Q5: Are there emerging therapies that threaten cysteamine hydrochloride's market share?

A5: Research into alternative delivery systems and new drugs for cystinosis could challenge market dominance, but none are yet mainstream.

---

Citations:

1. Mordor Intelligence. Cysteamine Market Analysis (2021).
2. U.S. Food and Drug Administration. Drug Approvals and Patents.
3. Global Data. Rare Disease Market Reports (2022).